
|Videos|October 18, 2016
How Myriad's myPlan Addresses the Risk of Recurrence in Lung Cancer
Author(s)Benjamin P. Levy, MD
Benjamin P. Levy, MD, discusses how Myriad's myPlan addresses the risk of recurrence in lung cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















